Professor Elyse Watkins, DHSc, PA-C, DFAAPA
Purpose: The purpose of this article is to provide a review of the most recent literature regarding the optimal treatment interval for dual antiplatelet therapy (DAPT) and the role of P2Y12 inhibitor monotherapy in patients with coronary artery disease (CAD) who have undergone percutaneous coronary intervention (PCI).
Method: A PubMed advanced literature search was completed implementing the search terms “dual antiplatelet therapy,” “PCI,” and “monotherapy.” Appropriate articles were identified and serve as the basis for this topic review.
Results: Search parameter filters applied include “best match” and “5 years or younger.” The preliminary search results numbered 56, but after applying various filters and excluding some articles for irrelevant content, 3 articles were selected. These articles include findings from the following randomized clinical trials: STOPDAPT-2 and SMART-CHOICE.
Conclusion: A reduction in bleeding events without an associated increase in death or major ischemic events was observed in patients who underwent PCI with drug-eluting stent placement and completed a shorter duration of DAPT followed by P2Y12 inhibitor monotherapy compared to patients completed a longer course of DAPT. Further research is required in other patient populations to account for the study’s limitations.
Keywords: dual antiplatelet therapy, PCI, monotherapy
Schacht EA. Optimal Length of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Role of P2Y12 Inhibitor Monotherapy. Lynchburg Journal of Medical Science. 2020; 2(4).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.